Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Autor: | Bernardes E; IPEN, São Paulo, Brazil., Caravan P; Massuchusetts General Hospital, Harvard University, Cambridge, USA., van Dam RM; University of California, Los Angeles, Los Angeles, USA., Deuther-Conrad W; Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Leipzig, Germany. w.deuther-conrad@hzdr.de.; Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. w.deuther-conrad@hzdr.de., Ellis B; Manchester University NHS Foundation Trust, Manchester, UK., Furumoto S; CYRIC, Tohoku University, Sendai, Japan., Guillet B; CERIMED, C2VN, Aix-Marseille Univ, Marseille, France., Huang YY; National Taiwan University College of Medicine, Taipei, Taiwan., Jia H; Beijing Normal University, Beijing, China., Laverman P; University of Alberta, Edmonton, Canada., Li Z; Xiamen University, Xiamen, China., Liu Z; Peking University, Beijing, China., Lodi F; S. Orsola-Malpighi Hospital, Bologna, Italy., Miao Y; University of Colorado, Denver, USA., Perk L; Radboud University Medical Center, Nijmegen, The Netherlands., Schirrmacher R; University of Alberta, Edmonton, Canada., Vercoullie J; University of Tours, Tours, France., Yang H; TRIUMF, Vancouver, Canada., Yang M; Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, People's Republic of China., Yang X; Peking University First Hospital, Beijing, China., Zhang J; Beijing Normal University, Beijing, China., Zhang MR; NIRS, Chiba, Japan., Zhu H; Peking University Cancer Hospital, Beijing, China. |
---|---|
Jazyk: | angličtina |
Zdroj: | EJNMMI radiopharmacy and chemistry [EJNMMI Radiopharm Chem] 2022 Apr 26; Vol. 7 (1), pp. 9. Date of Electronic Publication: 2022 Apr 26. |
DOI: | 10.1186/s41181-022-00162-3 |
Abstrakt: | Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Results: This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals and also a contribution in relation to MRI-agents is included. Conclusion: Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry. (© 2022. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |